Quotient Sciences is investing £6.3 million in its recently acquired manufacturing facility in Alnwick, UK, to significantly expand its drug substance manufacturing capability and create 80 new jobs over the next three years.
 
Quotient acquired the Alnwick facility from Arcinova in February 2021 to expand its services to include drug substance, drug product and clinical testing capabilities under one organization. The acquisition enables Quotient to support customers from candidate selection through commercial product launch. The investment will repurpose a 1,500 square-meter footprint and incorporate additional equipment and technologies, significantly expanding the number of new molecules developed each year.
 
Additional equipment, featuring advanced digital control and data capture, will support robust transfer from lab to multi-kilo scale production. Processing equipment with new developments in modular continuous technology will help maximize responsiveness and agility for manufacturing processes. The five-fold increase in scale will increase Quotient’s capacity by over 10 times for developing complex medicines.
 
“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” said Quotient Sciences SVP Candidate Development Services Roger Kilburn. “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”